363 related articles for article (PubMed ID: 28208664)
1. The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.
Boegemann M; Schlack K; Thomes S; Steinestel J; Rahbar K; Semjonow A; Schrader AJ; Aringer M; Krabbe LM
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208664
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.
Buttigliero C; Pisano C; Tucci M; Vignani F; Bertaglia V; Iaconis D; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
Acta Oncol; 2017 Apr; 56(4):555-562. PubMed ID: 28068151
[TBL] [Abstract][Full Text] [Related]
3. Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer.
Lozano Martínez AJ; Moreno Cano R; Escobar Páramo S; Salguero Aguilar R; Gonzalez Billalabeitia E; García Fernández R; De La Fuente Muñoz I; Romero Borque A; Porras Martínez M; Lopez Soler F; Cardenas Cánovas E; Ortega Martín I
Clin Transl Oncol; 2017 Dec; 19(12):1531-1536. PubMed ID: 28718070
[TBL] [Abstract][Full Text] [Related]
4. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.
de Wit R; Wülfing C; Castellano D; Kramer G; Eymard JC; Sternberg CN; Fizazi K; Tombal B; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Foster MC; Ozatilgan A; Geffriaud-Ricouard C; de Bono J
ESMO Open; 2021 Oct; 6(5):100241. PubMed ID: 34450475
[TBL] [Abstract][Full Text] [Related]
5. Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone.
Nieblas-Toscano D; Arenas-Bonilla AJ; Flores-Martín JF; Gutiérrez-Tejero F; Velarde-Muñoz C; Ramos-Alaminos CI; Salas-Moreno MC; Galisteo-Moya R; Moreno-Jiménez J
Actas Urol Esp (Engl Ed); 2020 Apr; 44(3):164-171. PubMed ID: 32035807
[TBL] [Abstract][Full Text] [Related]
6. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Sonpavde G; Pond GR; Armstrong AJ; Clarke SJ; Vardy JL; Templeton AJ; Wang SL; Paolini J; Chen I; Chow-Maneval E; Lechuga M; Smith MR; Michaelson MD
Clin Genitourin Cancer; 2014 Oct; 12(5):317-24. PubMed ID: 24806399
[TBL] [Abstract][Full Text] [Related]
8. Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer.
Conteduca V; Crabb SJ; Jones RJ; Caffo O; Elliott T; Scarpi E; Fabbri P; Derosa L; Massari F; Numico G; Zarif S; Hanna C; Maines F; Joyce H; Lolli C; De Giorgi U
PLoS One; 2016; 11(7):e0158952. PubMed ID: 27434372
[TBL] [Abstract][Full Text] [Related]
9. The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
Onal C; Sedef AM; Kose F; Oymak E; Guler OC; Sumbul AT; Aksoy S; Akkus Yildirim B; Besen AA; Muallaoglu S; Mertsoylu H; Ozyigit G
Future Oncol; 2019 May; 15(13):1469-1479. PubMed ID: 30977383
[TBL] [Abstract][Full Text] [Related]
10. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.
Nuhn P; Vaghasia AM; Goyal J; Zhou XC; Carducci MA; Eisenberger MA; Antonarakis ES
BJU Int; 2014 Dec; 114(6b):E11-E17. PubMed ID: 24529213
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of neutrophil-to-lymphocyte ratio in castration resistant prostate cancer: Single-centre study of Nigerian men.
Bello JO; Olanipekun OO; Babata AL
Niger J Clin Pract; 2019 Apr; 22(4):511-515. PubMed ID: 30975955
[TBL] [Abstract][Full Text] [Related]
12. Baseline neutrophil-lymphocyte ratio is associated with outcomes in patients with castration-resistant prostate cancer treated with Docetaxel in South China.
Jiang ZG; Liao SG
Medicine (Baltimore); 2021 Oct; 100(39):e27361. PubMed ID: 34596147
[TBL] [Abstract][Full Text] [Related]
13. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
Linton A; Pond G; Clarke S; Vardy J; Galsky M; Sonpavde G
Clin Genitourin Cancer; 2013 Dec; 11(4):423-30. PubMed ID: 23816526
[TBL] [Abstract][Full Text] [Related]
14. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.
Lorente D; Mateo J; Templeton AJ; Zafeiriou Z; Bianchini D; Ferraldeschi R; Bahl A; Shen L; Su Z; Sartor O; de Bono JS
Ann Oncol; 2015 Apr; 26(4):750-755. PubMed ID: 25538172
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.
Pei XQ; He DL; Tian G; Lv W; Jiang YM; Wu DP; Fan JH; Wu KJ
Int Urol Nephrol; 2017 Apr; 49(4):629-635. PubMed ID: 28161841
[TBL] [Abstract][Full Text] [Related]
16. High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy.
Yao A; Sejima T; Iwamoto H; Masago T; Morizane S; Honda M; Takenaka A
Int J Urol; 2015 Sep; 22(9):827-33. PubMed ID: 26087772
[TBL] [Abstract][Full Text] [Related]
17. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
Montgomery B; Kheoh T; Molina A; Li J; Bellmunt J; Tran N; Loriot Y; Efstathiou E; Ryan CJ; Scher HI; de Bono JS
Eur Urol; 2015 May; 67(5):866-73. PubMed ID: 25018037
[TBL] [Abstract][Full Text] [Related]
18. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
19. Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.
Chong W; Zhang Z; Luo R; Gu J; Lin J; Wei Q; Li B; Myers R; Lu-Yao G; Kelly WK; Wang C; Yang H
BMC Cancer; 2021 Jun; 21(1):655. PubMed ID: 34078304
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide.
Pisano C; Tucci M; DI Stefano RF; Turco F; Samuelly A; Bungaro M; Vignani F; Tarenghi F; Scagliotti GV; DI Maio M; Buttigliero C
Minerva Urol Nephrol; 2021 Dec; 73(6):803-814. PubMed ID: 33781017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
